Coherus BioSciences Company Profile (NASDAQ:CHRS)

Analyst Ratings

Consensus Ratings for Coherus BioSciences (NASDAQ:CHRS) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.50 (37.70% upside)

Analysts' Ratings History for Coherus BioSciences (NASDAQ:CHRS)
Show:
DateFirmActionRatingPrice TargetActions
7/27/2016Citigroup Inc.Initiated CoverageBuy$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016JPMorgan Chase & Co.Lower Price TargetOverweight$37.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Credit Suisse Group AGInitiated CoverageOutperform$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/23/2015Barclays PLCInitiated CoverageOverweight$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2014Cowen and CompanyInitiated CoverageOutperform$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Coherus BioSciences (NASDAQ:CHRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2016Q1($1.42)($1.67)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($1.74)($1.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($1.56)$488.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($1.22)$488.15 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/1/2011$0.01($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/2/2011$0.12$0.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Coherus BioSciences (NASDAQ:CHRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Coherus BioSciences (NASDAQ:CHRS)
DateHeadline
07/27/16 11:49 AMCiti Analyst Sees 45-60% Upside In Coherus Biosciences
07/27/16 05:36 AMCoverage initiated on Coherus BioSciences by Citigroup -
07/25/16 10:18 AMCoherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th - [at noodls] - REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2016 financial results will be released on August 9, 2016. At 4:30 ...
07/22/16 03:15 PMChecking in on Stock Volatility for: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Engelwood Daily
07/22/16 03:15 PMCoherus Biosciences Inc on Focus After Crashing In Today's Session - Consumer Eagle
07/22/16 03:15 PMEquity Roundup: Stock Performance Focus on Coherus BioSciences, Inc. (NASDAQ:CHRS) - Press Telegraph
07/22/16 03:15 PMCoherus BioSciences, Inc. (NASDAQ:CHRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 06:01 AMEarnings Focus and Crowd Sourced Sentiment Review for Coherus BioSciences, Inc. (NASDAQ:CHRS) - TGP
07/21/16 06:01 AMCoherus Biosciences Inc Just Recorded A Sigfniciant Increase - Press Telegraph
07/20/16 04:21 PMShares Jumping Higher in Session: Coherus Biosciences, Inc. (NASDAQ:CHRS) - TGP
07/20/16 11:14 AMCoherus Biosciences Incorporated (NASDAQ:CHRS) Sellers Increased By 2.15% Their Shorts - Consumer Eagle
07/19/16 09:28 AMInvestor Watch: Volatility Recap on Shares of: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Engelwood Daily
07/16/16 06:28 AMAnalyst Target and Average Rating Watch: Coherus BioSciences, Inc. (NASDAQ:CHRS) - Press Telegraph
07/13/16 03:17 PMCoherus BioSciences, Inc. (NASDAQ:CHRS) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 03:17 PMStocks Movements Activity: Rock Creek Pharmaceuticals, Inc. (PNK:RCPI) , Coherus BioSciences, Inc. (NASDAQ:CHRS) - Street Updates
07/13/16 03:17 PMBroker Outlook For Coherus BioSciences, Inc. (CHRS) - Fiscal Standard
07/13/16 03:17 PMCoherus Biosciences Inc. (CHRS) Is Climbing On Study Results - RTT News
07/12/16 03:19 PMCoherus Biosciences Inc. (CHRS) Rose To Over A 2-Month High On Study Results
07/12/16 07:28 AMCoherus Biosciences Inc. (CHRS) Rose To Over A 2-Month High On Study Results - RTT News
07/12/16 07:14 AMCoherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : July 12, 2016 -
07/11/16 03:12 PMCoherus Biosciences Inc. (CHRS) Is Climbing On Study Results
07/11/16 08:01 AMStock Rating Watch and Earnings Insight for Coherus BioSciences, Inc. (NASDAQ:CHRS) - Press Telegraph
07/11/16 08:01 AMCoherus BioSciences (CHRS) CHS-1701 Follow-on Study Met All co-Primary Endpoints - StreetInsider.com
07/11/16 07:30 AM8:30 am Coherus BioSciences Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic and Pharmacodynamic Biosimilarity Study -
07/11/16 07:30 AMCoherus Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic and Pharmacodynamic Biosimilarity Study - [GlobeNewswire] - REDWOOD CITY, Calif., July 11, 2016-- Coherus BioSciences, Inc., a leading global biosimilars company with late-stage clinical products, today reported topline results from its follow-on pharmacokinetic ...
07/10/16 03:05 PMNext Weeks Broker Price Targets For Coherus BioSciences, Inc. (CHRS) - Fiscal Standard
07/08/16 11:11 AMCan Coherus BioSciences, Inc. (NASDAQ:CHRS) Improve on the Earnings Front? - Engelwood Daily
07/08/16 11:11 AMCompany Stock Focus for Coherus BioSciences, Inc. (NASDAQ:CHRS): Which Way Will Shares Head? - Press Telegraph
07/07/16 08:28 PMOption Market: Coherus Biosciences Inc. Risk Hits An Elevated Level - CML News
07/06/16 07:58 AMTop Wall Street Stories: Gold Resource (NYSEMKT:GORO), Coherus Biosciences, (NASDAQ:CHRS), NICE Systems ... - KC Register
07/06/16 07:58 AMCoherus BioSciences, Inc. (NASDAQ:CHRS) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/01/16 11:18 AMCoherus BioSciences, Inc. (CHRS) Current Analyst Ratings - Fiscal Standard
06/30/16 11:00 AMUpdate on Stock Volatility for: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Engelwood Daily
06/30/16 11:00 AMBubbly Stocks in Focal Point- Coherus Biosciences (NASDAQ:CHRS), Gilead Sciences (NASDAQ:GILD), Corning ... - Seneca Globe
06/29/16 03:08 PMCoherus Biosciences Inc's Stock Is Buy After Today's Huge Increase - Press Telegraph
06/28/16 08:17 PMCheck on Share Volatility: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Engelwood Daily
06/28/16 08:17 PMCoherus BioSciences, Inc. (NASDAQ:CHRS) Company Rating and Target Watch - Telanagana Press
06/28/16 08:00 AMCoherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis - [GlobeNewswire] - Six Month Study Demonstrates Significant Reduction in Contrast-Enhancing Lesions Meeting Primary Endpoint. Safety and Tolerability Support Differentiated Product Profile. REDWOOD CITY, Calif., June 28, ...
06/27/16 07:47 AMCoherus BioSciences, Inc. (CHRS) Broker Price Targets For The Coming Week - Fiscal Standard
06/25/16 07:04 AMCoherus BioSciences, Inc. (NASDAQ:CHRS) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 10:15 AM3 Biotech Stocks to Buy in the Wake of the Brexit Vote -
06/24/16 04:48 AMCovering the Bases on Coherus BioSciences, Inc. (NASDAQ:CHRS): Where is the Stock Going? - Press Telegraph
06/23/16 04:38 PMNew Broker Ratings For Coherus BioSciences, Inc. (CHRS) - FTSE News
06/19/16 03:03 PMCoherus BioSciences, Inc. (CHRS) Analyst Price Targets For The Coming Week - Fiscal Standard
06/14/16 03:07 PMCOHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/13/16 02:40 PMCoherus BioSciences (CHRS) Announces Favorable PTAB Decision for IPR Petitions (ABBV) - StreetInsider.com
06/13/16 01:29 PMCoherus BioSciences Provides Update on IPRs - [at noodls] - REDWOOD CITY, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that ...
06/11/16 11:26 AMCoherus Presents Study Results Demonstrating Equivalence of its CHS-0214 Biosimilar to Etanercept: Biosimilar to etanercept meets primary endpoint
06/11/16 11:26 AMCoherus BioSciences (CHRS) Announces Results of Study Demonstrating CHS-0214 Equivalence to Enbrel
06/10/16 03:15 PMTrend Of Rating Given To Coherus BioSciences, Inc. (NASDAQ:CHRS) - Investor Newswire

Social

About Coherus BioSciences

Coherus BioSciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CHRS
  • CUSIP:
Key Metrics:
  • Previous Close: $25.78
  • 50 Day Moving Average: $19.06
  • 200 Day Moving Average: $18.09
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.01B
  • Beta: 4.92
  • Current Year EPS Consensus Estimate: $-6 EPS
  • Next Year EPS Consensus Estimate: $-5.19 EPS
Additional Links:
Coherus BioSciences (NASDAQ:CHRS) Chart for Thursday, July, 28, 2016